Background: Myelodysplastic syndromes (MDS) are a heterogeneous group of
hematopoietic disorders, which can be difficult to diagnose based only on morphologic bone …

Myelodysplastic syndromes are a heterogeneous group of clonal bone marrow disorders
characterized by dysplasia, progressive bone marrow failure, and increased risk of …

Diagnosis of myelodysplastic syndromes (MDS) relies on well‐defined cytomorphologic
criteria but is challenging in a significant number of patients. The detection of aberrant …

Mandatory for the diagnosis of myelodysplastic syndromes (MDS) is the presence of
dysplasia in> 10% of cells within one or more cell lineages or presence of> 15% ring …

Myelodysplastic syndromes (MDSs) are a heterogeneous group of hematopoietic stem cell
diseases categorized by dysplasia in one or more hematopoietic cell lineages, as well as …

Flow cytometry (FCM) is being increasingly evaluated for the diagnosis of myelodysplastic
syndrome (MDS). We employed multiple FCM approaches to assess MDS. Five-color FCM …

Abstract Abstract 2787 Background: Multiparameter flow cytometry (MFC) is capable of
detecting aberrant antigen expression related to myelodysplastic syndromes (MDS) and is …

The application of flow cytometry (FC) is recommended as part of the diagnostic approach
for MDS. The complexity of flow cytometric analysis of bone marrow cells in MDS has been …

The diagnosis and classification of myelodysplastic syndromes (MDS) are based on
cytomorphology (CM) and cytogenetics. A high degree of experience in CM is required to …

Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematopoietic stem
cell disorder characterized by morphological dysplasia which is subjective. There are …